Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
about
Population-level benefits from providing effective HIV prevention means to pregnant women in high prevalence settingsHigh medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
P2860
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Women with pregnancies had low ...... B randomized-controlled trial.
@ast
Women with pregnancies had low ...... B randomized-controlled trial.
@en
Women with pregnancies had low ...... B randomized-controlled trial.
@nl
type
label
Women with pregnancies had low ...... B randomized-controlled trial.
@ast
Women with pregnancies had low ...... B randomized-controlled trial.
@en
Women with pregnancies had low ...... B randomized-controlled trial.
@nl
prefLabel
Women with pregnancies had low ...... B randomized-controlled trial.
@ast
Women with pregnancies had low ...... B randomized-controlled trial.
@en
Women with pregnancies had low ...... B randomized-controlled trial.
@nl
P2860
P50
P1433
P1476
Women with pregnancies had low ...... B randomized-controlled trial.
@en
P2093
Leila E Mansoor
Lynn T Matthews
P2860
P304
P356
10.1371/JOURNAL.PONE.0056400
P407
P577
2013-03-05T00:00:00Z